| INTRODUCTION
Cardiovascular disease is a leading cause of significant morbidity and mortality. Dyslipidemia is a major modifiable risk factor for the development of cardiovascular disease, and one of the cornerstones in the prevention of cardiovascular events is a reduction in the level of lowdensity lipoprotein (LDL) cholesterol.
1,2
The most effective class of drugs for lowering the serum LDL cholesterol levels is 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitors, also known as statins.
3 Aggressive therapy to lower LDL cholesterol levels with various statins or the same statin at various doses has been reported to be associated with reduced rates of cardiovascular events. [4] [5] [6] [7] [8] However, despite the efficacy of statins having been established, the number of patients who achieve the lipid targets is still suboptimal, 9, 10 and increasing the dose of statin leads only to a limited reduction in the LDL cholesterol levels and is associated with a higher incidence of side effects. 11, 12 Therefore, further reducing the LDL cholesterol levels to the target goal using novel compounds or combination drug therapy with currently available drugs is of interest. 8, 13 Ezetimibe is a novel cholesterol absorption inhibitor that prevents cholesterol absorption by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein. 10, 14 NPC1L1 is an intestinal cholesterol transporter, 15 expressed in the brush border membrane of enterocytes in the small intestine. 16 Moreover, the NPC1L1 transporter is also expressed in the liver, where it reabsorbs cholesterol from bile.
17
Hence, ezetimibe decreases the plasma cholesterol levels by preventing cholesterol from being taken up by intestinal enterocytes and absorbed from the intestinal lumen and also restoring biliary cholesterol excretion.
15-18
Previous studies have reported the efficacy of combined therapy with ezetimibe and variable statins, with resulting reductions in the LDL Results: Fixed-dose combination of ezetimibe plus rosuvastatin significantly reduced LDL cholesterol, total cholesterol, and triglyceride levels compared with rosuvastatin alone. Depending on the rosuvastatin dose, these fixed-dose combinations of ezetimibe plus rosuvastatin provided LDL cholesterol, total cholesterol, and triglyceride reductions of 56%-63%, 37%-43%, and 19%-24%, respectively. Moreover, the effect of combination treatment on cholesterol levels was more pronounced in patients with DM or MetS than in non-DM or non-MetS patients, respectively, whereas the effect of rosuvastatin alone did not differ between DM vs non-DM or MetS vs non-MetS patients.
Conclusion:
Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels. Moreover, the reduction rate was greater in patients with DM or MetS.
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Cholesterol, Diabetes mellitus, Ezetimibe, Hypercholesterolemia, Metabolic syndrome, Rosuvastatin cholesterol levels of 12%-19%. 10, 13, 19, 20 Moreover, the IMPROVE-IT study recently demonstrated that the addition of ezetimibe to statin therapy resulted in a significantly lower risk of cardiovascular events.
Therefore, combined therapy with ezetimibe and statins may achieve not only incremental reductions in the LDL cholesterol levels, but may also improve the cardiovascular outcomes.
21
To date, a fixed-dose combination of ezetimibe and rosuvastatin
has not yet been developed and tested. Therefore, the objective of this study was to compare the LDL cholesterol-lowering effects of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin 5, 10, or 20 mg, as compared with rosuvastatin alone in patients with primary hypercholesterolemia. We also performed a subgroup analysis of safety and efficacy in patients with diabetes mellitus and metabolic syndrome.
| METHODS

| Study design
The After the lead-in period, the levels of LDL cholesterol and TG were assessed again and the patients who required lipid-lowering treatment according to the ATP III guidelines were finally enrolled in the study. Eligible patients were also required to have LDL cholesterol levels ≤250 mg/dL and TG levels <400 mg/dL at the second visit. The Participating subjects were centrally randomized in a 1:1 ratio to either fixed-dose combinations of ezetimibe 10 mg daily plus rosuvastatin or rosuvastatin alone. Specifically, eligible subjects were randomly assigned to one of the following six treatments for 8 weeks:
fixed-dose combinations of ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg daily) (combo therapy) or rosuvastatin alone (5, 10, or 20 mg daily) (monotherapy). Randomization was performed via a web-based online randomization system. All study personnel including the investigators, study site personnel, participants, monitors, and central laboratory personnel were blinded to the treatment allocation throughout the study.
| Efficacy and safety assessments
The primary efficacy endpoint was the percentage change from base- 
| Statistical analysis
| RESULTS
| Baseline characteristics
Of the 583 screened patients who entered the dietary lead-in period, daily)]). Overall, 3.9% and 2.5% of subjects who received combo therapy and monotherapy, respectively, discontinued the study treatment due to the withdrawal of consent. The compliance was similar between the treatment groups; at the end of the study, the compliance was 97% in the rosuvastatin-alone group and 96% in the combo therapy group.
The baseline characteristics were similar between the treatment groups in terms of demographic and clinical data ( 
| Efficacy
The fixed-dose combination of rosuvastatin and ezetimibe achieved significantly greater reductions in LDL cholesterol levels than rosuvastatin alone in the pooled data analysis, as well as in the compari- Table 2 ).
In terms of the other lipids, including total cholesterol, TG, non-HDL cholesterol, and apolipoprotein B, combo therapy showed significantly greater percent reductions than monotherapy in the pooled data analysis, as well as in the comparisons for each rosuvastatin dose, at both weeks 4 and 8 (Table 2, Figure 3 ). The HDL cholesterol levels increased in both treatment groups, with no difference observed between the two groups (Table 2, Figure 3 ). Figure 4 ). In other words, the potency of the combo therapy was greater in patients with DM than in non-DM patients, whereas the potency of the monotherapy was the same in both patients with DM and non-DM patients (combo therapy: patients with DM 64.2% vs non-DM patients −57.7%,
P=.008).
These results were similar to those observed for other lipids, including total cholesterol, non-HDL cholesterol, and apolipoprotein B (Table 3, Figure 4 ). The TG levels showed greater decreases with combo therapy than with monotherapy, and these decreases were comparable between patients with DM and non-DM patients ( Figure   S1 ). No significant differences were observed in HDL cholesterol and apolipoprotein A (Table 3, Figure S1 ). Figure 5 ). In other words, the potency of the combo therapy was greater in patients with MetS than in non-MetS patients, whereas the potency of the monotherapy was similar between patients with MetS and non-MetS patients (combo therapy: patients with MetS −63.9% vs non-MetS patients −57.6%, P=.013). These results were also similar to those observed for other lipids, including total cholesterol, non-HDL cholesterol, and apolipoprotein B (Table 4 , Figure 5 ). Combo therapy was more potent than monotherapy in reducing the TG levels and in elevating the HDL cholesterol levels, both in patients with and without MetS ( Figure S2 ).
Interestingly, the potencies of both combo therapy and monotherapy on the TG and HDL cholesterol levels were greater in patients with
MetS than in non-MetS patients ( Figure S2 ). No significant differences were observed in the apolipoprotein A levels ( Table 4 ).
The target LDL achievement rate was higher in patients treated with combo therapy than in patients treated with monotherapy ( 
| Safety
No serious drug-related adverse events (AEs) were reported. There were three serious AEs, including one in the monotherapy group (breast cancer) and two in the combo therapy group (left ulnar fracture and epigastric pain), although these were not considered drugrelated AEs by the investigators. The incidence of prespecified AEs was generally comparable between the two groups, with no clinically meaningful differences or statistical significance (Table S1 ). 
| DISCUSSION
This study sought to evaluate the effects of fixed-dose combination of rosuvastatin and ezetimibe compared to rosuvastatin alone in the Variables are presented as mean ± SD or n (%); SD, standard deviation; BMI, body mass index; CHD, coronary heart disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; R, rosuvastatin; E, ezetimibe.
treatment for primary hypercholesterolemia patients with LDL cholesterol levels above the ATP III recommended treatment targets. To our knowledge, the MRS-ROZE study is the first trial evaluating the safety and efficacy of fixed-dose combinations of rosuvastatin and ezetimibe in subjects with hypercholesterolemia.
The reduction in LDL cholesterol by fixed-dose combination therapy was significantly greater than that of rosuvastatin monotherapy in the pooled group, as well as in the subgroup comparisons for each rosuvastatin dose, at both weeks 4 and 8. Combo therapy produced an additional significant reduction in the baseline LDL cholesterol of Variables are presented as the least-squares means ± SEM; SEM, standard error of the mean; CI, confidence interval; LDL, low-density lipoprotein; HDL, high-density lipoprotein; R, rosuvastatin; E, ezetimibe. The reductions in LDL cholesterol were 43%, 52%, and 54% by rosuvastatin 5, 10, and 20 mg, respectively. Specifically, the reduction in LDL cholesterol in our study with rosuvastatin 10 mg was 52%, which is relatively higher than in previous studies that mainly evaluated were comparable to our result (52%) and also higher than the results of Western populations. Liao described that genetically based differences at the level of drug transporters and hepatic enzymes in the metabolism of statins would be the potential mechanisms of enhanced response to statins in Asians.
28
The incremental reduction in LDL cholesterol by ezetimibe in our study was 9.7%. Previous studies reported the reduction in LDL cholesterol differed according to the study design. Previous factorial studies reported the incremental reduction in LDL cholesterol with the addition of ezetimibe: 12.1% -13.8%. 10, 13, 20 Moreover, previous add-on studies reported higher incremental reduction in LDL cholesterol: 18.2 -25.2%. 19, 31, 32 The differences in baseline LDL cholesterol levels that might be affected by previously receiving statin therapy in add-on studies might explain the difference. The present study is a factorial study that compared the efficacy of combo therapy vs
Comparison of the percent changes in LDL cholesterol, TG, and HDL cholesterol between monotherapy and combo therapy for 8 wk: pooled data and data of the three different doses. Bars represent standard errors; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; LS means, least-squares means; R, rosuvastatin (pooled); E, ezetimibe 10 mg; R5, rosuvastatin 5 mg; R10, rosuvastatin 10 mg; R20, rosuvastatin 20 mg. *P<.05 for the specified between-treatment difference Variables are presented as mean ± SD or least-squares means ± SEM. SD, standard deviation; SEM, standard error of the mean; CI, confidence interval; R, rosuvastatin; E, ezetimibe; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
a Average doses of rosuvastatin in the pooled patients: R, 11.7 mg; R+E, 11.7 mg. b P value <.05 by ANCOVA between R+E in patients with diabetes vs R+E in nondiabetic patients.
F I G U R E 4
Greater reduction in cholesterol observed in patients with DM than in non-DM patients receiving combo therapy. Among patients receiving combo therapy, patients with DM exhibited greater reductions in cholesterol compared to non-DM patients, whereas patients with DM and non-DM patients receiving monotherapy showed comparable levels of cholesterol reduction. Bars represent standard errors; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; Apo B, apolipoprotein B; TC, total cholesterol; R, rosuvastatin; E, ezetimibe. *P<.05 for the specified between-treatment difference monotherapy after 4 weeks of therapeutic lifestyle changes and washout period. Based on this information, the incremental LDL cholesterol of 9.7% was comparable to previous results.
In our study, the efficacy of combo therapy in comparison with monotherapy on lowering LDL cholesterol was even greater in patients with DM than in non-DM patients. Diabetes has been listed as a CHD risk equivalent by ATP III. 22 Therefore, the LDL cholesterol goal for patients with diabetes is equivalent to that of patients with known CHD. 2 Previous studies have reported the improved effects of adding ezetimibe to simvastatin or rosuvastatin compared to statin monotherapy in patients with DM. [33] [34] [35] [36] In our study, we reproduced In addition, in our study, the potency of combo therapy was found to be more effective in patients with MetS compared with non-MetS patients. Previous studies have reported that the combination of ezetimibe with a statin produced a greater reduction in LDL cholesterol in patients with MetS, 39,40 especially for simvastatin. 41, 42 In this study using fixed-dose combinations, we confirmed that combo therapy is useful for patients with MetS, similar to patients with DM.
The results of other lipids, including total cholesterol, non-HDL cholesterol, and apolipoprotein B, also revealed that the differences in efficacy of combo therapy compared with monotherapy were more effective in patients with DM or MetS than in those without.
The safety and tolerability profiles observed in this study were generally comparable between the two groups and to those of previous studies of ezetimibe and rosuvastatin of similar duration. No drugrelated serious AEs were observed, and the incidence of muscle, liver, hepatitis-related, gastrointestinal-related, and allergic AEs was generally low and comparable between the two treatment groups and with other previous studies. However, although the results of this study showed comparative safety and efficacy of fixed-dose combination of rosuvastatin and ezetimibe vs rosuvastatin alone, the duration of the study was relatively short, limiting the ability to generalize these results to longer-term therapy.
In conclusion, the results of this study support the safety and efficacy of fixed-dose combination of rosuvastatin (5, 10, or 20 mg) and ezetimibe (10 mg) compared with rosuvastatin alone in patients with hypercholesterolemia. The benefits of fixed-dose combination treatment were more pronounced in DM and MetS patients.
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